{"id":2260,"date":"2026-06-10T17:00:00","date_gmt":"2026-06-10T20:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2260"},"modified":"2026-06-10T17:00:00","modified_gmt":"2026-06-10T20:00:00","slug":"rss-clinica-medicina-hematologia-oncologica-lla-lma-car-t-kymriah-yescarta-breyanzi-tmo-blinatumomab-inotuzumab","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-hematologia-oncologica-lla-lma-car-t-kymriah-yescarta-breyanzi-tmo-blinatumomab-inotuzumab\/","title":{"rendered":"RSS hemato onco: LLA, LMA, CAR-T, blinat"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de hematologia oncol\u00f3gica que reduzem RSS a descarte de seringa e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de hematologia oncol\u00f3gica<\/strong> + LLA leucemia linfobl\u00e1stica aguda B+T pedi\u00e1trico+adulto<\/strong> + LMA leucemia mieloide aguda + APL promieloc\u00edtica + ATRA + ATO ars\u00eanico<\/strong> + LMC LMC TKI imatinib+dasatinib+nilotinib+bosutinib+ponatinib + asciminib STAMP<\/strong> + LLC linfoma B + ibrutinib+acalabrutinib+zanubrutinib+venetoclax + glofitamab+epcoritamab BiTE<\/strong> + CAR-T Kymriah Novartis tisagenlecleucel + Yescarta Gilead axicabtagene ciloleucel + Breyanzi BMS lisocabtagene maraleucel + Carvykti Janssen ciltacabtagene autoleucel + Abecma BMS idecabtagene vicleucel<\/strong> + TCH TMO transplante c\u00e9lulas-tronco hematopoi\u00e9ticas aut\u00f3logo+alog\u00eanico+haploid\u00eantico REDOME REDOME-Cord<\/strong> + blinatumomab Blincyto BiTE CD19\/CD3 + inotuzumab Besponsa anti-CD22 ADC<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (LLA + LMA + LLC + LMC + LH + LNH + MM + MDS + MPN + amiloidose) + Grupo A4 (medula \u00f3ssea bi\u00f3psia crista il\u00edaca posterior + esterno + LP pun\u00e7\u00e3o lombar+IT) + Grupo B (citost\u00e1ticos hematol\u00f3gicos vincristina+doxo+ciclofosfamida+cytarabine+daunorubicina+idarubicina+mitoxantrona+L-asparaginase+pegaspargase+TKIs+venetoclax+ibrutinib+ATRA+ATO+CAR-T+TCR+blinatumomab+inotuzumab Lista C5) + Grupo E (perfuro Vacutainer + agulha bi\u00f3psia MO Jamshidi 11G+13G+coleta CMSP c\u00e9lulas-tronco af\u00e9rese Spectra Optia Terumo+CliniMACS Miltenyi). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para sangue venoso<\/strong> + ignoram especificidades hematol\u00f3gicas + CAR-T + TMO<\/strong> + subdimensionam Lista C5 citost\u00e1tico+CAR-T R$1-2.5M dose \u00fanica<\/strong> + perdem rastreabilidade transg\u00eanico OGM CAR-T<\/strong>. A realidade \u00e9 exatamente o oposto. RSS hemato onco opera em 5 fluxos hematol\u00f3gicos<\/strong> \u2014 LLA B+T (PRECOG+CALLA+ALL-IC-BFM+blinatumomab+inotuzumab+CAR-T Kymriah pedi\u00e1trico\/jovem adulto), LMA APL+n\u00e3o-APL (3+7 daunoxome+cytarabine+midostaurin FLT3+venetoclax+gilteritinib+enasidenib IDH2+ivosidenib IDH1+APL ATRA+ATO Lo-Coco), LMC TKI (imatinib Glivec+dasatinib Sprycel+nilotinib Tasigna+bosutinib Bosulif+ponatinib Iclusig T315I+asciminib Scemblix STAMP), CAR-T+TMO (Kymriah+Yescarta+Breyanzi+Carvykti+Abecma+TCH REDOME), BiTE+ADC+targeted (blinatumomab Blincyto+inotuzumab Besponsa+glofitamab Columvi+epcoritamab Epkinly DLBCL+venetoclax Venclexta+ibrutinib Imbruvica+acalabrutinib Calquence+zanubrutinib Brukinsa+pirtobrutinib Jaypirca+CD7+CD22+CD30 brentuximab Adcetris+CD79b polatuzumab Polivy+CD47 magrolimab+CD123 tagraxofusp Elzonris).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de hematologia oncol\u00f3gica, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos hematol\u00f3gicos oncol\u00f3gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS hemato onco tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
LLA B+T+blinat+CAR-T<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nKymriah pedi\u00e1trico<\/td>\n<\/tr>\n
LMA APL+ATRA+midost<\/td>\n4-11 kg\/dia<\/td>\nDi\u00e1ria<\/td>\n3+7+venetoclax<\/td>\n<\/tr>\n
LMC TKI+asciminib<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nGlivec+Tasigna+Iclusig<\/td>\n<\/tr>\n
CAR-T+TMO Carvykti<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nR$1-2.5M dose \u00fanica<\/td>\n<\/tr>\n
BiTE+ADC+ibrut+venet<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nBlincyto+Imbruvica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 14,5-40,5 kg\/dia<\/strong> em cl\u00ednica hemato onco m\u00e9dia porte.<\/p>\n

LLA + LMA + LMC + protocolos indu\u00e7ao+consolida\u00e7\u00e3o+manuten\u00e7\u00e3o: o est\u00e1gio agudo<\/h2>\n

A primeira camada \u00e9 leucemias agudas+cr\u00f4nica. Padr\u00e3o setorial inclui (a) LLA pedi\u00e1trico ALL-IC-BFM 2009 + COG AALL<\/strong> indu\u00e7\u00e3o vincristina+L-asparaginase Erwinaze+pegaspargase Oncaspar+daunorubicina+prednisona\/dexa + consolida\u00e7\u00e3o MTX altas doses + manuten\u00e7\u00e3o 6-MP+MTX 2-3 anos + IT methotrexate cytarabine hidrocortisona; (b) LLA adulto Hyper-CVAD\/CALGB 8811<\/strong> alternating + blinatumomab Blincyto Amgen BiTE CD19\/CD3 R\/R + inotuzumab Besponsa Pfizer anti-CD22 ADC R\/R + Ph+ TKI dasatinib\/imatinib\/ponatinib; (c) LMA n\u00e3o-APL 3+7<\/strong> indu\u00e7\u00e3o cytarabine 100-200 mg\/m\u00b2 7d + daunorubicina\/idarubicina 60-90 mg\/m\u00b2 3d + consolida\u00e7\u00e3o HiDAC + venetoclax Venclexta+azacytidina HMA Vidaza unfit\/elderly + midostaurin Rydapt FLT3-mutated CALGB 10603 + gilteritinib Xospata FLT3 R\/R + enasidenib Idhifa IDH2 + ivosidenib Tibsovo IDH1; (d) APL promieloc\u00edtica PML-RARA t(15;17)<\/strong> ATRA all-trans-retinoic acid Vesanoid 45 mg\/m\u00b2+ATO arsenic trioxide Trisenox 0,15 mg\/kg + APML4+Lo-Coco AML17 NEJM 2013 OS 99% + sem quimio + DIC differentiation syndrome dexa profil\u00e1tico; (e) LMC LMC fase cr\u00f4nica TKI<\/strong> imatinib Glivec Novartis 400-800mg + dasatinib Sprycel BMS+nilotinib Tasigna Novartis 2L+bosutinib Bosulif Pfizer+ponatinib Iclusig Takeda T315I-mutated + asciminib Scemblix Novartis STAMP allosteric.<\/p>\n

Cl\u00ednica com leucemias aguda+cr\u00f4nica madura escala LLA pedi\u00e1trico EFS 85-90%<\/strong> + escala LMA induction CR 65-80%<\/strong> + escala LMC OS >90% TKI<\/strong>. Como discutimos no post sobre linfoma cut\u00e2neo<\/a>, hemato onco \u00e9 base.<\/p>\n

CAR-T cell therapy Kymriah+Yescarta+Breyanzi+Carvykti+Abecma + TCH TMO REDOME: o est\u00e1gio celular<\/h2>\n

A segunda camada \u00e9 CAR-T+TMO. Padr\u00e3o setorial inclui (a) CAR-T DLBCL Yescarta Gilead axicabtagene ciloleucel ZUMA-1+ZUMA-7 1L high-risk + Breyanzi BMS lisocabtagene maraleucel TRANSCEND-NHL-001 + Kymriah Novartis tisagenlecleucel JULIET R\/R DLBCL + ELIANA pedi\u00e1trico LLA B<\/strong>; (b) CAR-T MM mieloma m\u00faltiplo<\/strong> Carvykti Janssen ciltacabtagene autoleucel CARTITUDE-1\/4 + Abecma BMS idecabtagene vicleucel KarMMa-1+KarMMa-3 + custo R$ 1-2,5M dose \u00fanica + apheresis CMSP CD3+ Spectra Optia Terumo + CliniMACS Prodigy Miltenyi + Lonza + Bristol Myers Squibb manufacturing 14-21 dias + lentiviral vector; (c) toxicidade CAR-T<\/strong> com CRS cytokine release syndrome ASTCT consensus grading 1-4 + ICANS immune effector cell-associated neurotoxicity syndrome + tocilizumab Actemra IL-6R + corticoide + anakinra + siltuximab; (d) TMO aut\u00f3logo<\/strong> com mobiliza\u00e7\u00e3o G-CSF Neulasta+plerixafor Mozobil + CMSP CD34+ \u22654-5\u00d710\u2076\/kg + condicionamento BEAM\/BU+CY\/melfalan altas doses + reinfus\u00e3o D0 + GVHD only alog\u00eanico; (e) TMO alog\u00eanico+haploid\u00eantico<\/strong> REDOME Registro Doadores Medula \u00d3ssea + REDOME-Cord cord blood + 10\/10 HLA + haploid\u00eantico PT-Cy posttransplant ciclofosfamida + GVHD profilaxia tacrolimus+MTX+rATG.<\/p>\n

Cl\u00ednica com CAR-T+TMO madura escala CAR-T DLBCL ORR 80%\/CR 50-60%<\/strong> + escala TMO alog\u00eanico OS 5y 50-70%<\/strong> + gerencia CRS+ICANS+GVHD<\/strong>. Conex\u00e3o com Lista C5 oncologia<\/a>.<\/p>\n

BiTE blinatumomab + inotuzumab + glofitamab + ibrutinib + venetoclax + brentuximab: o est\u00e1gio targeted<\/h2>\n

A terceira camada \u00e9 BiTE+ADC+targeted. Padr\u00e3o setorial inclui (a) blinatumomab Blincyto Amgen BiTE CD19\/CD3<\/strong> infus\u00e3o cont\u00ednua IC 4 semanas + LLA Ph- R\/R + MRD-positive E1910\/RIALTO + indu\u00e7\u00e3o BLAST + adultos+pedi\u00e1trico; (b) inotuzumab Besponsa Pfizer anti-CD22 ADC<\/strong> calicheamicin payload + INO-VATE LLA + R\/R B-ALL CR 80% vs 30% chemo + VOD veno-occlusive disease risco; (c) glofitamab Columvi Roche CD20\/CD3 BiTE<\/strong> DLBCL R\/R 3L + step-up dosing + epcoritamab Epkinly Genmab\/AbbVie CD20\/CD3 BiTE EPCORE-1 R\/R DLBCL+FL + mosunetuzumab Lunsumio Genentech FL; (d) CLL+MCL+WM ibrutinib Imbruvica Janssen+Pharmacyclics BTK<\/strong> + acalabrutinib Calquence AstraZeneca BTK + zanubrutinib Brukinsa BeiGene BTK + pirtobrutinib Jaypirca Lilly non-covalent BTK + venetoclax Venclexta AbbVie BCL-2 + obinutuzumab Gazyva CD20; (e) CD30 brentuximab Adcetris Takeda Hodgkin+ALCL<\/strong> + CD79b polatuzumab Polivy Genentech POLARIX + CD47 magrolimab Gilead + CD123 tagraxofusp Elzonris BPDCN + CD38 daratumumab Darzalex+isatuximab Sarclisa MM + bispecific MM teclistamab Tecvayli + elranatamab Elrexfio Lista C5.<\/p>\n

Cl\u00ednica com BiTE+ADC+targeted madura escala blinatumomab BLAST CR 32%<\/strong> + escala inotuzumab INO-VATE CR 80%<\/strong> + escala ibrutinib+venetoclax CLL CAPTIVATE OS prolonged<\/strong>. Conex\u00e3o com linfoma cut\u00e2neo<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade hemato onco<\/h2>\n

Cl\u00ednica hemato b\u00e1sica.<\/strong> 2 fluxos. Custo mensal R$ 12.000-32.000<\/strong> mas perda de CAR-T+TMO+BiTE.<\/p>\n

Cl\u00ednica hemato m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura LLA+LMA+LMC.<\/p>\n

Cl\u00ednica hemato completa 5 fluxos.<\/strong> LLA+LMA+LMC+CAR-T+BiTE + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 45.000-105.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura hematol\u00f3gica + CAR-T R$1-2.5M dose + Kymriah\/Yescarta\/Breyanzi\/Carvykti\/Abecma + APL ATRA+ATO OS 99%.<\/p>\n

Os tr\u00eas erros que aparecem em hemato onco<\/h2>\n

O primeiro \u00e9 a subdimensionamento CAR-T+OGM transg\u00eanico<\/strong>. Sem segrega\u00e7\u00e3o Kymriah+Yescarta+Breyanzi+Carvykti+Abecma + Lista C5 + biosseguran\u00e7a BSL-2 + lentiviral vector + CTNBio CIBio CQB + descarte espec\u00edfico OGM = n\u00e3o-conformidade ANVISA RDC 222 + n\u00e3o-conformidade Lei 11.105 Biosseguran\u00e7a + risco contamina\u00e7\u00e3o cruzada.<\/p>\n

O segundo \u00e9 a mistura LLA + LMA + LMC + linfoma<\/strong>. Confunde rastreabilidade neoplasia + impossibilita protocolos espec\u00edficos ALL-IC-BFM\/COG AALL\/Hyper-CVAD\/3+7\/imatinib + risco indica\u00e7\u00e3o inadequada CAR-T vs BiTE vs TKI vs venetoclax.<\/p>\n

O terceiro \u00e9 a falta de protocolo CRS+ICANS p\u00f3s-CAR-T<\/strong>. Sem ASTCT consensus grading 1-4 + tocilizumab Actemra dispon\u00edvel 24\/7 + corticoide + anakinra + UTI hematol\u00f3gica = risco mortalidade CRS grave + zero rastreabilidade adverse event.<\/p>\n

A regula\u00e7\u00e3o de RSS hemato onco no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com hematologia especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A ABHH Associa\u00e7\u00e3o Brasileira Hematologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS hemato onco 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a LLA pedi\u00e1trico ALL-IC-BFM 2009+COG AALL+vincristina+L-asparaginase Erwinaze+pegaspargase Oncaspar+daunorubicina+prednisona\/dexa+MTX altas doses+6-MP+MTX manuten\u00e7\u00e3o+IT MTX\/cytarabine\/hidrocortisona+adulto Hyper-CVAD\/CALGB 8811+blinatumomab Blincyto Amgen BiTE CD19\/CD3+inotuzumab Besponsa Pfizer anti-CD22 ADC+Ph+ TKI dasatinib\/imatinib\/ponatinib, LMA n\u00e3o-APL 3+7 cytarabine+daunorubicina\/idarubicina+HiDAC+venetoclax Venclexta+azacytidina Vidaza+midostaurin Rydapt FLT3 CALGB 10603+gilteritinib Xospata+enasidenib Idhifa IDH2+ivosidenib Tibsovo IDH1+APL PML-RARA t(15;17) ATRA Vesanoid+ATO Trisenox APML4+Lo-Coco AML17 OS 99%+DIC differentiation syndrome, LMC TKI imatinib Glivec+dasatinib Sprycel+nilotinib Tasigna+bosutinib Bosulif+ponatinib Iclusig T315I+asciminib Scemblix STAMP allosteric, CAR-T DLBCL Yescarta Gilead axi-cel ZUMA-1\/7+Breyanzi BMS liso-cel TRANSCEND+Kymriah Novartis tisa-cel JULIET+ELIANA pedi\u00e1trico LLA+MM Carvykti Janssen cilta-cel CARTITUDE-1\/4+Abecma BMS ide-cel KarMMa+R$1-2.5M dose+CMSP CD34+ af\u00e9rese Spectra Optia Terumo+CliniMACS Prodigy Miltenyi+CRS ASTCT+ICANS+tocilizumab Actemra+TMO aut\u00f3logo+alog\u00eanico+haploid\u00eantico PT-Cy+REDOME+REDOME-Cord+GVHD tacrolimus+MTX+rATG, BiTE blinatumomab Blincyto+inotuzumab Besponsa+glofitamab Columvi Roche CD20\/CD3+epcoritamab Epkinly Genmab\/AbbVie EPCORE+mosunetuzumab Lunsumio+ibrutinib Imbruvica BTK+acalabrutinib Calquence+zanubrutinib Brukinsa+pirtobrutinib Jaypirca non-covalent BTK+venetoclax Venclexta BCL-2+obinutuzumab Gazyva+brentuximab Adcetris CD30+polatuzumab Polivy POLARIX CD79b+magrolimab CD47+tagraxofusp Elzonris CD123 BPDCN+daratumumab Darzalex+isatuximab Sarclisa+teclistamab Tecvayli+elranatamab Elrexfio Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS hemato onco: LLA + LMA + CAR-T + TMO + blinatumomab. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2259,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2366,2120,3095,3096],"class_list":["post-2260","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-car-t","tag-hematologia","tag-lla","tag-lma"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2260"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2260\/revisions"}],"predecessor-version":[{"id":4353,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2260\/revisions\/4353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2259"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}